Dr. Rubin on Advantages With Whole-Exome Sequencing

Mark A. Rubin, MD
Published: Thursday, Apr 28, 2016



Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

By using whole-exome sequencing, researchers are able to cover 20,000 genes and have the ability to detect neoantigens—two things that targeted sequencing does not offer, Rubin explains. Because tumors are sequenced in germline, researchers are also able to examine for risk factors in patients' germline DNA with whole-exome sequencing.

Targeted sequencing does still have a prominent role in early-stage cancer, Rubin adds. However, when patients have advanced disease and drug resistance, whole-exome sequencing provides a better platform to understand this resistance.


Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

By using whole-exome sequencing, researchers are able to cover 20,000 genes and have the ability to detect neoantigens—two things that targeted sequencing does not offer, Rubin explains. Because tumors are sequenced in germline, researchers are also able to examine for risk factors in patients' germline DNA with whole-exome sequencing.

Targeted sequencing does still have a prominent role in early-stage cancer, Rubin adds. However, when patients have advanced disease and drug resistance, whole-exome sequencing provides a better platform to understand this resistance.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x